No Data
No Data
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
TORONTO, ON / ACCESSWIRE / June 19, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and dev
Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R)
TORONTO, ON / ACCESSWIRE / April 14, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and de
Earnings Call Summary | THERALASE TECHNOLOGIES INC(TLTFF.US) Q1 2024 Earnings Conference
The following is a summary of the Theralase Technologies Inc. (TLTFF) Q1 2024 Earnings Call Transcript:Financial Performance:Theralase's Q1 2024 total revenue decreased by 15% year-over-year.Gross mar
Theralase(R) Successfully Destroys Lung Cancer
TORONTO, ON / ACCESSWIRE / June 6, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF) is a clinical stage pharmaceutical company that is dedicated to the researc
Theralase(R) Release's 1Q2024 Financial Statements
TORONTO, ON / ACCESSWIRE / May 30, 2024 / Theralase Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research
Theralase(R) Expands Clinical Team
TORONTO, ON / ACCESSWIRE / May 2, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and devel